Abstract
Objective: The current study was undertaken to assess the effects of the treatment on ( IgA, IgG, IgM, CA125, CEA, migration inhibitory factor-related protein 14 (MRP14), stromal cell-derived factor 1 (SDF-1), fibroblast-specific protein 1 (FSP-1), and C-X-C Motif Chemokine Receptor 4 (CXCR4) in patients with advanced gastric cancer.
Methods: In this randomized clinical trial, 100 patients with gastric cancer were recruited after excluding 8 ineligible cases and assigned to receive either oxaliplatin (reference group) or the SOX regimen (observation group) via random number table method at a ratio of 1:1, with 50 patients in each group. The primary clinical endpoint was clinical efficacy, and secondary endpoints included immune function, tumor markers, and chemotherapy toxicities.
Results: The SOX regimen was associated with significantly higher clinical efficacy versus oxaliplatin monotherapy, as indicated by the higher disease control rate and objective remission rate (P<0.05). The SOX regimen provided better immunity recovery of patients versus oxaliplatin alone, evidenced by the higher levels of immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), CD3+, CD4+ and natural killer (NK) cells and lower CD8+ levels in the observation group (P<0.05). The SOX regimen provided markedly higher anti-tumor benefits than oxaliplatin monotherapy, evinced by the significantly reduced serum concentrations of tumor markers, including cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), migration inhibitory factor-related protein 14 (MRP14), stromal cell-derived factor 1 (SDF-1), fibroblast-specific protein 1 (FSP-1), and C-X-C Motif Chemokine Receptor 4 (CXCR4) (P<0.05). The SOX regimen was associated with a higher safety profile versus single oxaliplatin by reducing the occurrence of nausea and vomiting and leukopenia in patients (P<0.05).
Conclusion: The SOX regimen provides a viable treatment alternative for advanced gastric cancer management with favorable clinical efficacy. It enhances immune function, reduces tumor marker concentrations and toxic side effects of chemotherapy, and offers substantial prognostic benefits.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.